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Abstract 
 
This paper explores the adoption of redistributed manufacturing strategies by UK 
pharmaceutical firms. A multiple case study of six firms is coupled with expert opinion 
from academics in the fields of innovation, life sciences, pharmaceuticals and additive 
manufacturing. A triangulated data collection strategy is used including twenty-five semi-
structured interviews, eight focus groups and primary documentation. Drawing on 
adoption theory we identify the enablers of and barriers to the adoption of redistributed 
manufacturing strategies. The findings suggest that redistributed manufacturing will not 
replace existing supply chain configurations but instead complement them. Several 
potential niche applications for redistributed manufacturing are identified.  
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Introduction 
Increasingly complex and globally dispersed supply chains are creating significant risks 
for multinational firms. Pharmaceutical supply chains are particularly susceptible to the 
risk of disruption (Abdallah, 2013; Harrington and Najim, 2014). As pharmaceutical 
products are research and development intensive, complex to produce and heavily 
regulated, supply chains tend to be long, slow and expensive (Harrington and Najim, 
2014). Moreover, demand shocks can be quite unpredictable, as in the event of an 
epidemic. Uncertainty combined with long replenishment lead times tends to mean 
pharmaceutical firms hold significant inventory at various points in the chain (Calabrese 
and Pissavini, 2011). Typically, inventory equates to 30 – 90% of annual demand, with 
anywhere between 4–24 weeks’ worth of finished good stocks being held (Shah, 2004). 
Indeed, the top 25 pharmaceutical companies are said to hold inventory in the range of 
$100-150billion at any one point in time (Harrington and Srai, 2014). 
Redistributed manufacturing (RDM) is one potential remedy to the risks inherent in 
global pharmaceutical supply chains. RDM utilizes recent advances in manufacturing 
technology as a proactive strategy for risk mitigation. Used as an umbrella term, 
redistributed manufacturing captures the quickly changing supply chain structures 
associated with new manufacturing technologies such as additive manufacturing (3D 
printing) and continuous manufacturing (Pearson et al., 2013). These technologies 
 represent a shift away from the centralised batch manufacturing model towards smaller 
scale, localised manufacture for local markets. RDM is said to improve responsiveness to 
demand due to more localised, on-demand production possibilities (Campbell et al., 
2011). A shift from physical to digital designs reduces the need to transport finished parts 
and goods, instead placing emphasis on transporting raw materials and digitally sending 
designs to local production sites (ibid). The lessened reliance on transporting finished 
parts results in fewer nodes and reduced supply chain complexity (Birtchnell et al., 2013). 
Decreased complexity and improved responsiveness has profound consequences for 
managing supply chain risks as the probability and impact of disruptive events related to 
forecasting and inventory is significantly reduced (Petrovic et al., 2011). 
One technology particularly suited to the redistributed manufacturing model is 
additive manufacturing. The ability to additive manufacture drugs for immediate use can 
combat the tendency of some drugs to degrade on storage (Kommanaboyina and Rhodes, 
1999). Additive manufacture opens up the possibility of personalized medicine where 
individualized combinations of drugs could be produced, helping to ensure patient 
compliance (Içten et al., 2015). The technology can also create more porous pills allowing 
faster drug release, helpful in cases where oral delivery of pills is difficult (Sandler et al., 
2011). Moreover, entirely new formulation types of molecular substrates with complex 
drug release profiles could be produced, presenting the possibility of treating many 
chronic conditions that are currently out of reach (Khaled et al., 2014).  
Due to the potential benefits of redistributed manufacturing we attempt to answer the 
question: how can pharmaceutical firms adopt redistributed manufacturing strategies? To 
answer this question we draw on adoption theory to develop a theoretical framework for 
the adoption of redistributed manufacturing strategies. The next section reviews the 
literature pertinent to answering the research questions of interest. The third section 
presents the findings from multiple case studies in the U.K. pharmaceutical industry. The 
paper concludes by outlining the theoretical and managerial contribution of the paper. 
 
Literature Review 
In the 1990’s, the construct of supply chain risk management (SCRM) emerged to help 
firm’s manage the increasing complexity associated with the globalization of supply 
chains. SCRM is defined as “the management of supply chain risk through coordination 
or collaboration among the supply chain partners so as to ensure profitability and 
continuity” (Tang, 2006). Since its inception, SCRM scholars have identified many types 
of supply chain risks including forecast risks, intellectual property risks, inventory and 
systems risks, financial flow risks, delays and disruptions (Chopra and Sodhi, 2004; Tang 
and Musa, 2011). Innovation, particularly innovation on the part of suppliers, has been 
advanced as one means of addressing supply chain risks (Choi and Krause, 2006). 
Innovation can be understood as “new combinations” of new or existing knowledge, 
resources, equipment and so on (Schumpeter, 1934 p. 65). The adoption of innovation 
has been an area much studied in the management literature (i.e. Frambach and 
Schillewaert, 2002; Rogers, 2003). According to Rogers (2003) an organizations’ 
decision to adopt an innovation occurs over five stages. During the agenda setting stage 
an organization identifies problems which may create a perceived need for an innovation 
and the environment is scanned for innovations of potential value. During the second 
stage, an innovation is identified which can address a firm’s problems and the fit between 
them is planned and designed (matching stage). In the third stage, the innovation is re-
invented to address the perceived problems and organizational structures are altered to 
accommodate the innovation (restructuring and re-invention stage). The organization then 
clarifies the relationship between the innovation and the organization more clearly as the 
 innovation is put into regular use (clarification stage). Finally, the innovation loses its 
separate identity and becomes an element in the organizations ongoing activities 
(routinizing stage) (Rogers, 2003). 
The perception of organizational decision makers affects their evaluation of and 
propensity to adopt an innovation (Frambach and Schillewaert, 2002). For an 
organization to be persuaded to adopt an innovation it must demonstrate a relative 
advantage to the incumbent technology (Anderson and Narus, 1990). Moreover, the 
innovation must be perceived as being compatible with the existing values and needs of 
potential adopters (Rogers, 2003). Other factors that influence the likelihood of adoption 
include complexity and whether a potential adopter can trial the innovation (ibid). The 
final factor is the ability to observe the results and benefits of the innovation. Of these 
factors, relative advantage and complexity are said to have the greatest impact on how 
quickly a new technology is adopted (ibid).  
 
Research Method 
We apply Rogers’ (2003) innovation adoption stage model to understand the uptake 
of redistributed manufacturing strategies in the pharmaceutical industry. A multiple case 
study design is selected as it offers in-depth data gathering and analysis opportunities 
(Dyer and Wilkins, 1991). Moreover, a multiple case study design allows within and 
across case comparisons and is often consider more robust then single case designs (Yin, 
2014). Data is gathered from six case companies, four of which are global leaders in the 
pharmaceutical sector and two smaller U.K. based firms. A comparison between large 
and small firms allows us to control for the effects of organizational size. In addition to 
the case companies, expert opinion is gathered from leading academics in the fields of 
innovation, additive manufacturing, life sciences and pharmaceuticals.  
To improve the validity and reliability of the findings we used a triangulated data 
collection method (Yin, 2014) including twenty-five semi-structured interviews and eight 
focus groups which was then objectively verified using primary and secondary data 
sources. A snowball sampling technique was used to select each interviewee (Taylor and 
Bogdan, 1998). Data collection stopped when a point of theoretical saturation was 
reached (Eisennhardt, 1989). NVIVO 10 software was used to code the interview 
transcripts, focus group notes and company documentation. Using hierarchical coding, 
groups of similar codes were clustered together to produce themes which, in combination, 
provided a rich story about the case (Eisennhardt and Graebner, 2007). 
 
Findings 
The following section relates the research findings to Rogers’ (2003) innovation adoption 
model. In so doing, several enablers of and barriers to the adoption of redistribution 
manufacturing innovations are identified.  
 
Stage 1: Agenda Setting Stage 
During the agenda setting stage an organization identifies problems which may create 
a perceived need for an innovation and the environment is scanned for innovations of 
potential value. The SCRM literature has identified several potential problems, or risks, 
associated with globalized supply chains. Additional risks, particular to the 
pharmaceutical industry, were identified during data collection (see Table 1). These risks 
include single sourcing arrangements where large multinational pharmaceutical firms are 
reliant upon one primary manufacturing supplier. In such an arrangement, pharmaceutical 
firms are oftentimes only a small proportion of the supplier’s order book, creating an 
imbalance of power in favour of the supplier. Another significant challenge is overcoming 
 the regulatory challenges of switching suppliers. Suppliers have to adhere to Good 
Manufacturing Practices (GMP) and be certified by agencies such as the Food and Drug 
Administration, a process that may take several years. Finally, insufficient capacity was 
found to exist within the centralised distribution model used by multinational 
pharmaceutical firms. Lack of capacity restricted the ability to flexibly respond to demand 
spikes with companies often having to stop production of one product, to give priority to 
the production of an urgent drug (see Table 1). 
 
Table 1: Problems identified during the agenda setting stage 
Stage Theme Code Quote from Interviewee 
Agenda 
Setting 
Stage 
Current 
problems 
faced by 
global 
pharma 
supply 
chains 
Single-
sourcing 
arrangements 
in primary 
manufacture 
 “There is a total imbalance of power. So we are locked 
in and suppliers know it too well. So we need to find new 
ways of ensuring that you will be perceived as a preferred 
customer by your most critical suppliers.” 
 
“We have several hundred materials that only one 
company in the world produces, and there is no 
alternative. Those are impossible because they are 
registered, it's IP, you cannot even develop alternative 
suppliers to build up the same thing, And for those, the 
best risk mitigation is to be as friendly as possible and 
very close”  
  Regulatory 
challenges 
associated 
with 
switching 
suppliers 
“For critical suppliers we're talking about years. The 
cycle time is very long... if the extent of the change 
implies some clinical trials, forget about it, it can then be 
very costly and very long… it can take more than five 
years.” 
 
“We're not in a position to just freely pick up and put 
down suppliers at the drop of a hat. It would need to be a 
fairly serious issue.” 
  Lack of 
production 
capacity 
which 
restricts 
ability to 
flexibly 
respond to 
fluctuations 
in demand 
“So if you’re already running 24/7 shifts and you’ve got 
a full order book, then the opportunity to reprioritise is 
limited. If you’ve been optimising your supply strategy, 
your buffers of product to enable you to turn something 
off for a period of time would also be impacted.”  
 
“We've rationalised globally the number of sites we use 
a company. So I think if you look at it like that there's less 
net capacity than there was…with these capacity 
challenge these days, you do end up with stock outs, the 
problem is that we just don't have enough global 
capacity.” 
 
March (1981) asserts that innovation adoption by organizations is often driven less by 
problems than by solutions. Most organizations face a multitude of problems but possess 
knowledge of only a few innovations that offer solutions. If one begins with a solution, 
there is a good chance that the innovation will match some problem that is facing the firm. 
Consequently, most organizations continuously scan for innovations and match any 
promising innovation found with some relevant problem (March, 1981). A similar 
problem solving approach was apparent at each of the case companies, particularly in the 
instance of additive manufacturing. As one focus group participant explained: “3D 
Printing is like a solution looking for a problem.” The conundrum faced by the case 
companies was how to suitably match the innovation to the right problem.  
  
Stage 2: Matching Stage 
During the matching stage an innovation is identified which can address a firm’s problems 
and the fit between them is planned and designed. For a decision maker to be persuaded 
to adopt an innovation it must demonstrate a relative advantage to the incumbent 
technology (Rogers, 2003). In many industries, additive manufacturing is being looked 
upon as revolutionary technology that will replace current manufacturing processes. In 
aerospace, for example, additive manufacturing is seen as a technology that will replace 
current casting and forging processes (Gibson et al., 2014). Aerospace firms are interested 
in the technology’s ability to print lighter weight parts, which reduces engine weight and 
therefore improves fuel usage, the most significant cost to airlines. Similarly, automotive 
firms see additive manufacturing as a technology that can reduce vehicle weight and offer 
more customized products for consumers (Manyika et al., 2013).  
Despite the widespread adoption of additive manufacturing in aerospace and 
automotive, this study did not find the same rate of uptake in the pharmaceutical industry. 
More specifically, interviewees did not see additive manufacturing as a technology that 
would disrupt current manufacturing processes. Instead, it was suggested that additive 
manufacturing would act as a complementary innovation that functioned alongside 
current production technologies. This sentiment is captured in the following quote:  
 
“One of the challenges associated with introducing people to 3D printing is this 
preconceived idea that they’ll use it to print something they already have. And usually 
though, that product has been manufactured with that manufacturing technology in 
mind. This is a different technology that uses a different way of forming things that 
has different advantages compared to other ways. So you have to really think about, 
what do you want out of your product and can 3D printing realise that?” 
 
This quote suggests that, in the pharmaceutical industry at least, additive manufacturing 
is not likely to radically transform current manufacturing methods, certainly not in the 
near term. The questions then arises of whether additive manufacturing needs to 
demonstrate a relative advantage over incumbent technologies to be adopted. The quotes 
captured in Table 2 suggests this may not be the case.  
 
Table 2: Ability to demonstrate a relative advantage to incumbent technology 
Stage Theme Code Quote from Interviewee 
Matching 
Stage 
Innovation’s 
ability to 
demonstrate 
a relative 
advantage 
to 
incumbent 
technology 
Does not 
need to 
demonstrate 
a relative 
advantage 
as not a 
replacement  
“Many evangelists, if you like, in this industry say ‘3D 
printing is a substitute technology to others’. However, the 
more conservative approach is to say ‘okay, they 3D 
printing technology will be some sort of complement to 
actual manufacturing lines” 
 
“My personal opinion would be that 3D printing will be 
just part of the spectrum of manufacturing technologies, so 
it will somehow be embedded within an existing supply 
chain.”  
 
“There is a kind of, a myth that additive manufacturing, 3D 
printing, will replace all traditional manufacturing. And 
that is not likely to ever happen. It will be a complimentary 
technology that will enable you to do different things.”  
 
 Here we find a slight difficulty with Rogers’ (2003) innovation adoption model. He 
argues that to persuade organizational decision makers to adopt an innovation it must 
demonstrate a relative advantage over the incumbent technology. Yet, the findings 
suggest that additive manufacturing is not likely to act as a replacement, but instead as a 
complementary technology. Such a technology does not easily fit into Rogers’ model. We 
are then left to explore other factors that may be inhibiting the rate of adoption. Table 3 
suggests it is not the complexity of additive manufacturing but instead the lack of 
complexity in the control systems that monitoring product quality that is slowing the rate 
of adoption. An inability to verify the quality of manufactured products creates challenges 
in getting the process certified by regulators.  
 
Table 3: Complexity and ease of use by potential innovation adopter 
Stage Theme Code Quote from Interviewee 
Matching 
Stage 
Complexity-
ease of use by 
potential 
adopter 
Lack of 
robust 
quality 
control 
system 
affecting 
likelihood 
of 
adoption  
“These machines are still very primitive. Everyone 
thinks they’re really complicated and they’re really 
advanced, but the technology still is quite young and 
in many cases the maturity and process stability isn’t 
quite ready because the technology doesn’t really 
have advanced control systems yet.” 
 
“This is one of the issues with the technology itself, 
is that additive manufacturing is, in terms of its 
control systems, still very simple and primitive. And 
one thing these machines don’t do well is monitor the 
process for quality control.” 
 
Another possible factor affecting adoption is that additive manufacturing technology is 
not currently compatible with the needs of the pharmaceutical sector. Specifically, 
interviewee’s explained that a significant amount of capital is invested in the centralized 
manufacturing model. Centralized facilities take advantage of global demand volume to 
manufacture generic and small molecule drugs at a very low cost. Interviewee’s argued 
that due to the sunk capital and the cost advantages of the centralized, model it would be 
very difficult to make a business case for redistributed technologies such as additive 
manufacturing.  
Several focus group members stressed that a clear need had to first be identified for 
pharmaceutical firms to be persuaded to adopt the technology. One focus group member 
suggested the best way to identify the value proposition for additive manufacturing is to 
start from the patient and work back up the supply chain. Figure 1 suggests the supply of 
pharmaceuticals can be split into three categories, including advanced therapy medicinal 
products (ATMP’s), small molecule and large molecule/biologics.  
 
 
Figure 1.0- identifying the value proposition of redistributed manufacturing. 
 
 The resounding view of interviewees was that additive manufacturing would not be 
suitable for the mass production of small molecule and generic pills because of the sunk 
costs and low production prices of the current centralized model (see Table 4). Instead, 
additive manufacturing may be more applicable to advanced therapeutics and large 
molecule drugs because they are more expensive to manufacture and tend to have higher 
profit margins; thereby justifying the high costs of additive manufacturing machines (see 
Table 4).  
 
Table 4: Compatibility with needs of adopting organization 
Stage Theme Code Quote from Interviewee 
Matching 
Stage 
Is innovation 
compatible 
with needs of 
potential 
adopter  
RDM not 
suitable for 
small 
molecule- 
generic drugs 
or replacing 
established 
production 
networks 
 
 
For ATMPs and biologics it might make sense. 
But for small molecules? I would suggest, forget 
it. You're not going to get drug manufacturing to 
be distributed for small molecule products 
 
Where it doesn’t add value is where you have 
good distribution networks and you have a 
product that can get through those distribution 
networks in a timeframe that meets the patient 
need but also meets any product restrictions and 
requirements. We then have to ask ourselves 
‘okay, so what are the circumstances when that 
doesn’t work so well?’ 
 
“The cost is probably going to go up, so what's 
the benefit of having a local plant that can do it? 
Because you've got regulatory issues, you've got 
quality issues, What are the practicalities of 
running a duplicate outfit somewhere else, when 
you could just make your current facility 
bigger?” 
 
Several interviewees argued that for additive manufacturing to be adopted a viable 
application had to first be identified and then trialled by potential adopters. As suggested 
by Rogers (2003), the easier it is for individuals to see the results of an innovation, the 
more likely they are to adopt it. It was suggested that a small niche activity should be 
chosen, one that no commercial company wanted to touch because of scale and 
complexity (see table 5). Interviewees argued that the ability to demonstrate the 
technology from research and development through to proof of an integrated development 
system, would make the case for the technology and increase the likelihood of adoption.  
 
Table 5: Trialability- ability to test innovation prior to adoption 
Stage Theme Code Quote from Interviewee 
Matching 
Stage 
Trialability 
– ability to 
demonstrate 
innovation 
Additive 
manufacturing 
needs to 
trialled before 
it can be 
adopted 
“I think to get started you need to find little 
niche that nobody else wants to do because of 
scale and complexity” 
 
“You start with something the big players don't 
want to be doing anyway, and then you slowly 
get better at it and eat their lunch in 10 years' 
time. Actually being able to do it, and show 
you can do it as an integrated development 
system, and application, makes the case for the 
technology” 
  
Table 5 summarizes some of the potential products suited to a redistributed manufacturing 
approach including gene therapies that are custom tailored to the individual patient. Other 
potential applications include compound products such as infusion bags that are uniquely 
tailored to the patient (see Table 6). Pharmaceutical firms are hesitant to develop such 
products through conventional means as each change in product/packaging interaction 
requires a stability study making costs prohibitive.  
Late-stage dispensing was also suggested as a suitable application for redistributed 
manufacturing. In the UK, the Pharmaceutical Society has recently permitted 
decentralised dispensing opening up the possibility of hospital pharmacies using additive 
manufacturing to produce drug combinations. Additive manufacturing could address the 
wasteful process currently being used of de-blistering pill packs from the manufacturer. 
The production of radioactive pharmaceuticals is another potentially viable option which, 
in effect, already uses a redistributed manufacturing model. In the radio pharmacy model 
a hospital pharmacists prepares the radioactive injectable on-site allowing it to be 
administered to a patient in a matter of hours before it dissipates. Additive manufacturing 
could complement such a model with the product created on-site and administered 
immediately based on patient need (see Table 6).  
Focus group participants felt additive manufacturing could also help the clinical 
trial process. Currently pharmaceutical firms need to develop a manufacturing screen to 
reach stage three trials. Once the clinical trial process begins, the sponsor is quite tightly 
bound to the specific compound that is being tested; changes to the compound itself or 
even the manufacturing process need to be reported to regulators and could, 
hypothetically, invalidate study results. Additive manufacturing’s ability to produce a 
variety of compounds, within the confines of a defined manufacturing process, could 
permit more flexibility during drug development and validation. Finally, it was suggested 
that redistributed manufacturing technologies would fit humanitarian aid situations where 
infrastructure is damaged or non-existent. In such a situation bulk active ingredients could 
be shipped to the point of need and the final product, such as a vaccine, printed as required 
(see Table 6).  
 
Table 6: Observability- ability to test innovation prior to adoption 
Stage Theme Code Quote from Interviewee 
Matching 
Stage 
Observability  Additive 
manufacturing 
is best suited 
to customized 
niche products 
required on a 
small scale 
“Compounding is an example where, we had 
some discussion within NHS England when 
they said ‘Actually what we'd really like you to 
do is just deliver infusion bags ready for patient 
use. We don't really want our pharmacies to 
have to do that anymore’. That would be near-
to-hospital, near-to-point-of-use, which would 
be personalised to that individual. That's an 
unmet need, definitely.” 
 
“An area closer to distributive manufacturing is 
late-end dispensary. Redistributed 
manufacturing in this setting may address a very 
common practice and a very wasteful one when 
hospitals de-blister tablets from a manufacturer 
and use those de-blistered formulations to make 
new formulations within the hospital. They 
could just prepare the formulation without 
having to de-blister and reuse the tablet using 
 additive manufacturing, it may solve that 
problem” 
 
“There is one model that's been around for 
decades called radio pharmacy, for radioactive 
medicines. So, some of them are treatments, 
some of them are diagnostics, made at the 
hospital. You have a mini-manufacturing plant 
and within 15 minutes, you make the radioactive 
pharmaceutical injectable, out of an additive 
manufacturing machine. It's preparing a specific 
product for a specific patient, at a specific dose, 
at the time of use.”  
 
Conclusion 
Despite the rising popularity of redistributed manufacturing technologies in the aerospace 
and automotive sectors, such a strategy appears to have gained limited traction in the U.K. 
pharmaceutical industry. The research findings suggest that the industry is largely still at 
stage two (matching stage) of Rogers (2003) innovation adoption model. While 
pharmaceutical firms are aware of the problems associated with the centralized 
manufacturing model, sunk costs and volume advantages make the likelihood of additive 
manufacturing generic and small molecule drugs highly unlikely. Instead, the findings 
suggest that redistributed manufacturing technologies are better used to complement 
existing supply chain configurations. If the basic tenets of Rogers’ adoption model hold 
true then redistributed manufacturing technologies may not be adopted by the 
pharmaceutical industry until they are viewed a complementary as opposed to 
replacement innovations.  
 
Theoretical Contribution 
Rogers (2003) innovation adoption model states that relative advantage and complexity 
are the two primary factors that influence the adoption decision. We argue that because 
redistributed manufacturing technologies complement existing processes there is not a 
requirement to demonstrate a relative advantage to incumbent technologies. Moreover, 
we find that it is not complexity, but actually a lack of complexity in terms of quality 
control processes that is slowing adoption. This paper contributes to theory by identifying 
that when an innovation is complementary as opposed to disruptive, the key factors 
influencing adoption will be compatibility, trialability and observability. It was found that 
for redistributed manufacturing technologies to be adopted, a definite need had to first be 
identified. Potential adopters should then be given the opportunity to trial the technology 
and witness the results and benefits. The ability to demonstrate and test the technology 
on niche products within a redistributed model would likely quicken the pace of industry 
adoption. 
 
Managerial Contribution 
The paper highlights to managers the enablers of and barriers to the adoption of 
redistributed manufacturing in the pharmaceutical industry. Managers are encouraged to 
see redistributed manufacturing as a complementary strategy to their current centralized 
production model. The study highlights to managers some potential applications of RDM 
including the use of additive manufacturing to create compound products such as infusion 
bags. Other existing re-distributed models could be further explored such as radio 
pharmacy where radioactive drugs are created at the hospital for immediate patient use. 
Late stage dispensing using additive manufacturing technology could cut down on the 
 waste currently generated from de-blistering. Managers are encouraged to identify other 
potential applications for RDM within their own supply chains. 
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